Bio-Path Holdings announced positive preclinical results for BP1001-A, a potential obesity and Type 2 diabetes treatment. The drug candidate successfully reversed palmitic acid-induced insulin resistance in liver cells, mirroring earlier positive results in muscle cells. This progress builds on previous findings demonstrating the drug’s ability to restore insulin signaling by downregulating Grb2 expression.
This development is potentially impactful for addressing the growing prevalence of obesity and Type 2 diabetes, conditions often linked to insulin resistance. A successful therapy targeting this mechanism could offer a new approach to managing these interconnected metabolic disorders, improving patient outcomes and potentially reducing the burden on healthcare systems. Specifically, the ability of BP1001-A to counteract the negative effects of a high-fat diet at the cellular level suggests it may be effective in preventing or treating insulin resistance, a key driver of these diseases.
BP1001-A, a modified version of Bio-Path’s prexigebersen (BP1001) currently in Phase 2 trials for blood cancers, functions by downregulating Grb2, a protein involved in insulin signaling. The next preclinical step involves testing in a mouse model to assess the drug’s impact on weight, insulin sensitivity, and glucose tolerance. Pending positive results, Bio-Path anticipates filing an Investigational New Drug (IND) application in 2025 for a Phase 1 clinical trial.
These preclinical findings are a promising step toward a potential new therapeutic option for obesity and Type 2 diabetes. Success in the upcoming animal studies and subsequent clinical trials could position BP1001-A as a valuable asset in Bio-Path’s pipeline, potentially expanding the drug’s application beyond oncology into metabolic disease. Further research will be crucial to determining its efficacy and safety in humans.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
